
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising company with a bright future ahead. Their innovative technology platform, the ABC platform, has shown great potential in the development of retinal medicines. Their investigational medicines, tarcocimab tedromer, KSI-501, and KSI-101, have shown positive results in clinical trials, giving confidence in their potential for approval and commercial success. With data expected in the coming quarters and a strong financial position, Kodiak Sciences is a company to watch in the biopharmaceutical sector.
Bears say
Kodiak Sciences is currently in the pre-commercial stage with three late-stage clinical programs in development, however, they face numerous risks including binary risks surrounding future datasets, potential regulatory delays, and the requirement to build a global infrastructure for sales and marketing which could increase cash burn and result in dilution for shareholders. In addition, the success of Kodiak's proprietary ABC platform relies on their ability to manufacture biologics, and their issued patents will expire relatively soon, leaving the company vulnerable to competition.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares